Tagged with Global

Global In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer’s Upjohn generics unit finally closed a USD 12 billion merger. The combined new company, ‘Viatris’, boasts a global workforce of over 45,000, 50 manufacturing sites, and a presence in 165 countries,…

Global Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he has put in place for the business, and the key issues of manufacturing and access.   Cell and gene therapies are truly…

Global David H. Crean summarizes the recent 39th annual J.P. Morgan Healthcare Conference 2021 that was held in a virtual format, noting potential changes in format for future events. Crean does, however, underline the importance of the Conference for industry networking and highlights some of the biopharma topics to watch under…

Global Rare disease patient advocate Monica Weldon outlines some of the ethical conundrums around embryonic gene editing. With CRISPR technology again in the news as part of the rush to develop COVID-19 treatments and vaccines, Weldon highlights the arguments for and against embryonic gene editing from a patient/parent perspective and makes…

Global In a wide-ranging and exclusive interview with PharmaBoardroom, Ipsen CEO David Loew looks back on an atypical first 100 days at the helm of the iconic French mid-cap; its EUR 3 billion war chest for bolt-on acquisitions; planned expansions in rare- and ultra-rare diseases; and the niche oncology segments where…

Global Four companies (GSK, Pfizer, Sanofi, and MSD) together occupy over 80 percent of the global market for vaccines. Moreover, vaccines are an important part of these companies’ revenue streams, making up between 13 and 21 percent of total revenues in 2019.   Made with Visme Infographic Maker   Insights on Vaccines’…

Global Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts become reality, stakeholders from across the globe will need to collaborate to ensure these vaccines are available and accepted. Vaccines will need a high level of trust for a return…

Global DHL’s Larry St Onge outlines how the logistics giant adapted to the COVID-19 pandemic in 2020, the unprecedented cross-industry collaboration that emerged, and the potential for long-term transformation of biopharmaceutical distribution and logistics.   Supply chains will never be the same as they were pre-pandemic. This is now the “new-normal”…

Global With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more widely, notably the 30-year wait for a HIV vaccine. Janssen Global Therapeutic Area Head of Vaccines Johan Van Hoof recently sat down with PharmaBoardroom to discuss the…

Global After a transformative 2020, Shawview Consulting’s Brendan Shaw looks into his crystal ball and makes five predictions (plus one) on the key trends that life sciences companies need to be aware of in 2021.   If 2020 taught us anything, it is that futurists and forecasters make their new year…

Global Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market.   Remegen RemeGen,…

Global While great strides in gender diversity has been made within healthcare boardrooms and leadership teams globally, as well as more generally across the workplace and many other arenas in many countries, at times we are served a stark reminder that the fight for greater gender equality and women representation is…